Zenas BioPharma: Obexelimab Is Being Graded On The Wrong Curve Zenas BioPharma (ZBIO) is advancing ...

Zenas BioPharma: Obexelimab Is Being Graded On The Wrong Curve Zenas BioPharma (ZBIO) is advancing obexelimab for IgG4-RD, with FDA acceptance and a May 2027 PDUFA date, positioning as a long-term maintenance therapy. ZBIO maintains a sizable cash runway, with pro forma balances covering operations into late 2028, though financing risk remains if FDA approval is delayed. Obexelimab's non-depleting B cell inhibition offers a differentiated safety profile versus Uplizna, targeting chronic use in older patients and potentially expanding the addressable market.